ATAI Life Sciences NV has announced an update on the Phase 2b trial of inidascamine, a treatment for cognitive impairment associated with schizophrenia $(CIAS)$. Initial results indicate a numerical improvement in cognitive and functional measures across both active treatment arms compared to a placebo. However, the study did not achieve statistical significance on the primary endpoint. The safety and tolerability profile of inidascamine remains favorable. Recognify Life Sciences, a subsidiary of ATAI, plans to present additional results at upcoming scientific meetings. The company will continue to evaluate strategic options for inidascamine based on the comprehensive data set, which will include secondary endpoints and subgroup analyses.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。